DBV Technologies to Participate in Upcoming Investor Conference

Rhea-AI Summary

DBV Technologies (Euronext: DBV, Nasdaq: DBVT) announced its participation in the 5th Annual Evercore ISI HealthCONx Conference from Nov. 29 to Dec. 1, 2022. CEO Daniel Tassé will engage in a Fireside Chat on Nov. 30 at 8 a.m. ET and hold one-on-one investor meetings. A live webcast of the session will be available on the company's website, with a replay accessible for 90 days post-event. DBV Technologies focuses on developing Viaskin™, a non-invasive immunotherapy technology, targeting food allergies, particularly through its ongoing clinical trials of Viaskin Peanut.

Montrouge, France, November 22, 2022

DBV Technologies to Participate in Upcoming Investor Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 5th Annual Evercore ISI HealthCONx Conference taking place Nov. 29 – Dec. 1, 2022. Daniel Tassé, Chief Executive Officer, will participate in a Fireside Chat session on Wednesday, Nov. 30, at 8 a.m. ET, as well as one-on-one investor meetings throughout the day.

A live webcast of the fireside chat will be available on the Investors & Media section of the Company’s website: https://wsw.com/webcast/evercore29/dbvt/2371680.

A replay will also be available on DBV Technologies’ website for 90 days after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

Viaskin and EPIT are trademarks of DBV Technologies.

Attachment

• PDF Version

FAQ

When is DBV Technologies participating in the Evercore ISI HealthCONx Conference?

DBV Technologies will participate in the Evercore ISI HealthCONx Conference from November 29 to December 1, 2022.

What time is DBV’s Fireside Chat at the Evercore ISI HealthCONx Conference?

DBV's Fireside Chat is scheduled for November 30, 2022, at 8 a.m. ET.

How can I watch DBV Technologies' Fireside Chat?

You can watch DBV Technologies' Fireside Chat live on their Investors & Media section of their website.

What is Viaskin and how is it related to DBV Technologies?

Viaskin is DBV Technologies' investigational platform for immunotherapy, focused on delivering treatments for food allergies.

What is the ticker symbol for DBV Technologies?

The ticker symbol for DBV Technologies on the Nasdaq is DBVT.